SCHEMBL1521487

SCHEMBL1521487

CSc1ncc(CCl)c(NC(C)C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.38
HTT P42858 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.32
SRC P12931 2/20 0.31
ABL1 P00519 1/20 0.31
SYK P43405 1/20 0.31
ITGB1 P05556 1/20 0.31
ITGA4 P13612 1/20 0.31
GLP1R P43220 1/20 0.31
HCK P08631 1/20 0.30
PIM1 P11309 1/20 0.30
SMN1; SMN2 Q16637 2/20 0.30
TSHR P16473 1/20 0.30
HSD17B10 Q99714 1/20 0.30
CYP1A2 P05177 1/20 0.30
MITF O75030 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30955646 0.84 AOC1 (0.40) TRPM8HTTKDM4EMEN1KMT2A
SCHEMBL3968862 0.84 AOC1 (0.40) TRPM8HTTKDM4EMEN1KMT2A
SCHEMBL1521541 0.84 HTT (0.48) TRPM8HTTKDM4EMEN1KMT2A
SCHEMBL25658788 0.83 TRPM8 (0.40) TRPM8HTTKDM4EMEN1KMT2A
SCHEMBL24170657 0.83 TRPM8 (0.37) TRPM8HTTKDM4EALDH1A1SYK
SCHEMBL1521534 0.82 LMNA (0.39) HTTKDM4EMEN1KMT2AALDH1A1
SCHEMBL29541506 0.82 LMNA (0.39) HTTKDM4EMEN1KMT2AALDH1A1
SCHEMBL1837239 0.82 TRPM8 (0.39) TRPM8HTTKDM4EMEN1KMT2A
SCHEMBL24225121 0.82 HTT (0.39) TRPM8HTTKDM4EMEN1KMT2A
Hydrochloric Acid SCHEMBL3582648 0.81 LMNA (0.38) HTTKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
CN-101516379-A Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS LLC (US) 2009-08-26 CN disclosed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 TRPM8 1761/4885HTT 1148/4885KDM4E 2009/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 TRPM8 1761/4885HTT 1148/4885KDM4E 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.